Keywords: successful, early, termination, sutent, trial, sends, pfizer

Successful early termination of Sutent trial sends Pfizer shares up 10%

Article | 23 March 2009

Print This

Global drug giant Pfizer's Sutent (sunitinib malate) has shown a significant benefit in the treatment of pancreatic islet cell tumors, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in